|
|
|
|
Elutia Inc (NASDAQ: ELUT) |
|
|
|
| |
ELUT's Revenue Growth by Quarter and Year
Elutia Inc 's Revenue results by quarter and year
|
Select the Comparisons :
|
|
Select the Ratio:
|
|
| ELUT Revenue (in millions $) |
FY 2025 |
FY 2024 |
FY 2023 |
FY 2022 |
| 4th Quarter |
December |
-
|
6.32
|
6.53
|
12.67
|
| 3rd Quarter |
September |
-
|
5.74
|
5.84
|
12.39
|
| 2nd Quarter |
June |
-
|
5.80
|
9.98
|
12.64
|
| 1st Quarter |
March |
5.46
|
5.84
|
13.05
|
11.50
|
| FY |
|
5.46
|
23.70
|
35.40
|
49.20
|
| ELUT Revenue first quarter 2025 Y/Y Growth Comment |
Elutia Inc reported decrease in Revenue in the first quarter 2025 by -6.56% to $ 5.46 millions, from the same quarter in 2024.
The decrease in the first quarter 2025 Elutia Inc 's Revenue compares unfavorably to the Company's average Revenue decrease of -2.76%.
Looking into first quarter 2025 results within Biotechnology & Pharmaceuticals industry 31 other companies have achieved higher Revenue growth. While Elutia Inc ' s Revenue decline of -6.56% ranks overall at the positon no. 2459 in the first quarter 2025.
|
| ELUT Revenue ( Y/Y Growth %) |
2025
|
2024 |
2023 |
2022 |
| 4th Quarter |
December |
- |
-3.22 % |
-48.46 % |
16.67 % |
| 3rd Quarter |
September |
- |
-1.71 % |
-52.87 % |
7.83 % |
| 2nd Quarter |
June |
- |
-41.88 % |
-21.04 % |
3.95 % |
| 1st Quarter |
March |
-6.56 % |
-55.25 % |
13.48 % |
-10.71 % |
| FY |
|
- |
-33.05 % |
-28.05 % |
3.82 % |
ELUT Revenue (Quarter on Quarter Growth %) |
2025
|
2024 |
2023 |
2022 |
| 4th Quarter |
December |
- |
10.1 % |
11.82 % |
2.26 % |
| 3rd Quarter |
September |
- |
-1.03 % |
-41.48 % |
-1.98 % |
| 2nd Quarter |
June |
- |
-0.68 % |
-23.52 % |
9.91 % |
| 1st Quarter |
March |
-13.66 % |
-10.57 % |
3 % |
5.89 % |
| FY (Year on Year) |
|
- |
-33.05 % |
-28.05 % |
3.82 % |
| Revenue Y/Y Growth Statistics |
| High |
Average |
Low |
| 91.41 % |
-2.76 % |
-50.06 % |
| (Sep 30 2022) |
|
(Jun 30 2024) |
|
|
| Revenue Y/Y Growth Statistics |
| High |
Average |
Low |
| 91.41 % |
-2.76 % |
-50.06 % |
| (Sep 30 2022) |
|
(Jun 30 2024) |
|
| Revenue by Quarter for the Fiscal Years 2022, 2023, 2024, 2025 |
Elutia Inc 's Q/Q Revenue Growth
| Revenue Q/Q Growth Statistics |
| High |
Average |
Low |
| 11.8 % |
-4.16 % |
-41.47 % |
| (Dec 31 2023) |
|
|
| ELUT's I. Quarter Q/Q Revenue Comment |
In the I. Quarter 2025 Elutia Inc disclosed drop in Revenue from the fourth quarter by -13.66% to $ 5.46 millions, from $ 6.32 millions achived in the previous reporting period.
But that's not important problem, as Elutia Inc 's Revenue generally seem to plunge in this quarter.
Within Biotechnology & Pharmaceuticals industry 38 other companies have achieved higher Revenue quarter on quarter growth. While Elutia Inc 's Revenue growth quarter on quarter, overall rank is 2241. |
|
|
|
| Revenue Q/Q Growth Statistics |
| High |
Average |
Low |
| 11.8 % |
-4.16 % |
-41.47 % |
| (Dec 31 2023) |
|
|
| ELUT's I. Quarter Q/Q Revenue Comment |
In the I. Quarter 2025 Elutia Inc disclosed drop in Revenue from the fourth quarter by -13.66% to $ 5.46 millions, from $ 6.32 millions achived in the previous reporting period.
But that's not important problem, as Elutia Inc 's Revenue generally seem to plunge in this quarter.
Within Biotechnology & Pharmaceuticals industry 38 other companies have achieved higher Revenue quarter on quarter growth. While Elutia Inc 's Revenue growth quarter on quarter, overall rank is 2241. |
|
Elutia Inc 's 12 Months Revenue Growth Year on Year
Revenue TTM Growth |
12 Months Ending
(Mar 31 2025) |
12 Months Ending
(Dec 31 2024) |
12 Months Ending
(Sep 30 2024) |
12 Months Ending
(Jun 30 2024) |
12 Months Ending
(Mar 31 2024) |
| Cumulative Revenue 12 Months Ending |
$ 23.32 |
$ 23.71 |
$ 23.91 |
$ 24.01 |
$ 28.19 |
| Y / Y Revenue Growth (TTM) |
-17.28 % |
-33.03 % |
-42.43 % |
-50.06 % |
-44.44 % |
| Year on Year Revenue Growth Overall
Ranking |
# 2603 |
# 2446 |
# 2781 |
# 1599 |
# 902 |
| Seqeuential Revenue Change (TTM) |
-1.63 % |
-0.86 % |
-0.42 % |
-14.83 % |
-20.36 % |
| Seq. Revenue Growth (TTM) Overall
Ranking |
# 2459 |
# 2291 |
# 2825 |
# 2065 |
# 1408 |
| Cumulative Revenue growth Comment |
Elutia Inc showed decline, but improvement compare to trailing twelve month Revenue decrease in Dec 31 2024. If the fiscal year would end in Mar 31 2025, Elutia Inc 's annual Revenue fall would be -17.28% year on year to $23 millions.
In the Healthcare sector 379 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 2446 to 2603. |
|
|
| Revenue TTM Y/Y Growth Statistics |
| High |
Average |
Low |
91.41 % |
-2.76 % |
-50.06 % |
|
|
|
| Revenue TTM Q/Q Growth Company Ranking |
| Within: |
No. |
| Industry |
# 32 |
| Sector |
# 343 |
| S&P 500 |
# 2459 |
|
| Cumulative Revenue growth
Comment |
Elutia Inc showed decline, but improvement compare to trailing twelve month Revenue decrease in Dec 31 2024. If the fiscal year would end in Mar 31 2025, Elutia Inc 's annual Revenue drop would be -17.28% year on year to $23 millions.
In the Healthcare sector 379 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 2446 to 2603. |
| Revenue TTM Y/Y Growth Statistics |
| High |
Average |
Low |
91.41 % |
-2.76 % |
-50.06 % |
|
|
|
| Revenue TTM Q/Q Growth Company Ranking |
| Within: |
No. |
| Industry |
# 32 |
| Sector |
# 343 |
| S&P 500 |
# 2459 |
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
